No profile data available.
Orgenesis Inc. (ORGS) is a healthcare company in the drug manufacturing contractors industry, based in Germantown, United States, with about 77 full-time employees.
It reported revenue of $1.04 million for fiscal year 2024, up 95.3% from fiscal year 2023, and net income of -$48.17 million. Its largest business segment, Octomera, brought in 50% of segment revenue in fiscal year 2024. Its market capitalization was $3.43 million as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 8, 2026.
, a biotech company, focuses on cell and gene therapies in the United States. It operates through two segments: Octomera and Therapies.
Orgenesis reported $1.04 million in revenue for fiscal year 2024, up 95.3% from $530,000 in fiscal year 2023.
Octomera, with $533,000 or 50% of segment revenue in fiscal year 2024. Next: Therapies (50%).
$3.43 million as of October 8, 2026.
Listed companies of a similar size in the same industry (drug manufacturing contractors) include FibroGen, Inc. (FGEN), Pluri Inc. (PLUR), Bio Green Med Solution, Inc. (BGMS), Scinai Immunotherapeutics Ltd. (SCNI).